A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled parallel arm study will assess efficacy and
safety and the effects of taspoglutide on cardiovascular events in patients with inadequately
controlled type 2 diabetes mellitus and established cardiovascular disease. Patients will be
randomized to receive either taspoglutide subcutaneously (sc) 10mg weekly for 4 weeks
followed by 20mg sc weekly, or weekly sc placebo, in addition to background
anti-hyperglycemic medication and standard of care treatment for cardiovascular disease.
Anticipated time on study treatment is up to 2 years. Target sample size is 2000 patients.